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INTRODUCTION 
Quetiapine Fumarate is a white to off-white crystalline 
powder. Drug having efficacy in the treatment of 
schizophrenia and bipolar disorder is mediated through a 
combination of dopamine type 2 (D2) and serotonin type 2 
(5HT2) antagonisms. An atypical antipsychotic, 
Quetiapine fumarate (2-[2-(4-dibenzo [b, f] [1, 4] 
thiazepin-11-yl-1-piperazinyl) ethoxy] ethanol fumarate 
(2:1 salt)) which has a unique receptor- binding profile 
belonging to a new chemical class, the dibenzothiazepine 
derivatives
1
. Quetiapine is an antagonist at a broad range 
of neurotransmitter receptors. Quetiapine is used in the 
treatment of schizophrenia or manic episodes associated 
with bipolar disorder. As a consequence, there is an 
increasing demand for new analytical methods for 
determination of same drug in most economical way. 
Several stability indicating HPLC methods were reported 
for the determination of Quetiapine
2
, most of these require 
ultraviolet detection as Quetiapine is not electro active, 
some stability indicating, impurity characterizing, some 
they reported for determination of the drug in human 
plasma
3-5
. A HPTLC method was also developed and 
reported in the literature
6
. However none of these methods 
is sensitive enough for determination of the expected drug 
levels and some of them are time consuming and require 
complex sample pretreatment or long run times. Some Gas 
Chromatography–High Performance Liquid 
Chromatography (GC–HPLC) methods were also 
employed
7
. Some UPLC–MS methods were published for 
determination of Quetiapine 
8-9
. The goal of our work was 
to develop a Stability Indicating Reverse Phase HPLC 
method for determination of Quetiapine in solid dosage 
form and to use the results for analysis of drug in 
pharmaceuticals in most economic way, as rapid and 
effective ways for determination of drugs in simple 
manner  by Chromatography method is desirable because 
such methods are not that much (analytical papers) 
available as per our knowledge for the quality control of 
pharmaceutical formulations containing Quetiapine by RP 
HPLC. The chemical structure for the drug was 
represented in Fig. no. 1. To the best of our knowledge, 
none of the currently available analytical methods can 
separate all the known related compounds and degradation 
impurities of Quetiapine dosage form.  
 
Figure 1: Chemical Structure of Quetiapine fumarate 
Quetiapine pharmaceutical formulation is also not official 
in any pharmacopoeia yet. Furthermore, there is no less 
time-consuming and stability-indicating RP-RPLC method 
reported in the literature. Also the cost of the analysis 
using LCMS, GC/MSD and LC-MS-MS is very high and 
also very delicate instrument are needed compared to RP-
HPLC with respect to routine quality control analysis. 
ABSTRACT 
This study was designed to develop and validate a simple, sensitive, precise, and specific stability indicating reverse phase 
high-performance liquid chromatographic (HPLC) method for estimation of QuetiapineFumarate in bulk and its tablet dosage 
form. The HPLC separation was carried out by reverse phase chromatography on Thermo column Symmetry C18 (4.6 x 
150mm, 5 m) with a mobile phase composed Sodium dihydrogen phosphate and the pH was adjusted to 4.0 by 
Orthophosporic Acid & Methanol in the ratio of 35:65 v/v in isocratic mode at a flow rate of 1.0 ml/min. The run time was 
maintained for 6mins. The detection was monitored at 290 nm. The calibration curve for QuetiapineFumarate was linear from 
20 to60 µg/ml. The inter-day and intra-day precision was found to be within the limits. The proposed method was adequate 
sensitivity, reproducibility, and specificity for the determination of QuetiapineFumarate in bulk and its tablet dosage forms. 
The limit of detection [LOD] and limit of quantification [LOQ] for QuetiapineFumarate were found to be 0.01 µg/ml and 0.03 
µg /ml respectively. The Accuracy recoveries were 100.0-100.4% and reproducibility was found to be satisfactory.The bulk 
active pharmaceutical ingredient was subjected to  thermal,  photolytic,  hydrolytic  (acidic  and  basic)  and  oxidative  stress  
conditions  and  stressed  samples  were analyzed by the proposed method. The method was validated in terms of linearity, 
precision, accuracy, specificity and robustness. All the validation was done as per ICH guidelines. The proposed method was 
simple, fast, accurate, and precise for the quantification ofQuetiapineFumarate in the dosage form, bulk drugs as well as for 
routine analysis in quality control. 
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Hence, we focused on developing a selective, fast, cost-
effective and stability-indicating method using this 
advance technique (RP-HPLC) for the assay determination 
of Quetiapine in solid pharmaceutical dosage forms. Hence 
a reproducible stability-indicating RP-UPLC method was 
developed which is less time-consuming and more 
selective compared to the all present methods, which takes 
only about 5 min for a single run. Thereafter, this method 
was successfully validated according to the ICH 
guideline
10-11
. 
MATERIAL & METHOD 
12
 
Chemical and Reagent Used: The following chemicals 
were procured for the process Water [HPLC Grade],  
Quetiapine [Working Standards], Methanol [HPLC 
Grade], Ortho phosphoric acid all these chemicals were 
procured from STANDARD SOLUTIONS and HCL [LR 
Grade]procured from FINAR CHEMICAL LIMITED, 
NaOH [L R Grade]procured from S D FINE- CHEM 
LIMITED & H2O2 procured from ALPHA PHARMA 
LIMITED. The tablet [25mg Label Claim] was collected 
from the Local market and the manufacturer was Lupin 
Company. The brand name of the tablet is Placidine-25mg. 
 
 
Apparatus and Chromatographic Conditions: 
Equipment  : High performance liquid chromatography equipped with Auto Sampler sand DAD or  
UV detector. (Waters, Alliance 2695 Separation Module with 2487 UV Vis Detector) 
Column   :  Symmetry C18 (4.6 x 150mm, 5 m Make: Thermo) 
Flow rate  :  1.0mL per min 
Wavelength  :  290 nm 
Injection volume  :  20 l 
Temperature      :  Ambient 
Run time   :  6.0 min 
Detector                :  Photo diode array [For Force Degradation Studies] 
Soft ware               :  Empower 2 
Model No              :  2996 
MFD by                 :  WATERS 
 
Preparation of Sodium Dihydrogen Phosphate buffer
13-
15
:  The Buffer Solution was prepared by weighing 
accurately and transferred 2.5mg of sodium dihydrogen 
phosphate into a 1000ml volumetric flask, dissolved and 
diluted to 1000ml with Water [HPLC grade]. The pH was 
adjusted to 4.0 with Orthophosphoric acid. 
Preparation of mobile phase: The above mixture was 
taken [Buffer Solution] 350mL (35%) and 650 mL of 
Methanol HPLC (65%) mixed thoroughly and degassed in 
ultrasonic water bath for 5 minutes. Then it was filtered 
through 0.45 µ filter under vacuum filtration. 
Diluent Preparation: The Mobile phase was used as 
diluent. 
Preparation of the Quetiapine Standard & Sample 
Solution: 
Standard Solution Preparation: The Standard Stock 
Solution was prepared by weighing accurately and 
transferred 10mg of Quetiapine [Working standard] into a 
10 mL               volumetric flask. About 7 mL of diluent 
was added and sonicated to dissolve it completely and the 
volume was made up to the mark with the same solvent. 
Further from the above Stock Solution pipette out 0.4 ml 
solution into a 10ml volumetric flask and diluted up to the 
mark with the diluent. The resultant solution was mixed 
well and then it was filtered through 0.45µm filter. 
Sample Solution Preparation:  The Sample Stock 
Solution was prepared by weighing accurately 5 
Quetiapine Tablets and calculated the average weight. 
Further accurately weighed and transferred the sample 
equivalent to 10 mg of Quetiapine into a 10 mL volumetric 
flask. About 7 mL of the diluent was added and sonicated 
to dissolve it completely and the volume was made up to 
the mark with diluent. The resultant solution was mixed 
well and then it was filtered through 0.45µm filter. Further 
from the above Stock Solution pipette out 0.4 ml solution 
into a 10ml volumetric flask and diluted up to the mark 
with diluent. The resultant solution was mixed well and 
then it was filtered through 0.45µm filter. 
Procedure for Injecting the Sample & Standards in the 
Chromatographic System
16-17
: About 20 L of the 
standard and sample solutions were injected into the 
chromatographic system and measured the area for the 
Quetiapine peak and calculated the %Assay by using the 
suitable formulae.  
System Suitability Results
18-19
: The Tailing factor for the 
peak due to Quetiapine in Standard solution should not be 
more than 2.0. The theoretical plates for the Quetiapine 
peak in Standard solution should not less than 2000. 
Assay Calculation Formulae: 
Assay % = 
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Where:  
AT = Peak Area of Quetiapine obtained with test 
preparation 
AS = Peak Area of  Quetiapine obtained with standard 
preparation 
 WS = Weight of working standard taken in mg 
 WT = Weight of sample taken in mg  
 DS = Dilution of Standard solution 
 DT = Dilution of sample solution 
 P     = Percentage purity of working standard  
Results obtained for the Assay: 
System Suitability Results: 
 1). The Tailing factor Obtained from the standard 
injection was 1.5. 
 2). The Theoretical Plates Obtained from the 
standard injection was 4324.4. 
Assay Result Obtained: 
 Weight of 5 tablets: 0.5510 grams 
 Average Weight     : 0.1030grams 
       
       
 
  
  
 
   
  
 
  
  
 
  
    
 
    
   
 
     
  
           
VALIDATION DEVELOPMENT
20-22
 
1.  Precision: The precision of an analytical procedure 
expresses the closeness of measurements obtained from 
multiple sampling of the same homogenous sample 
under the prescribed conditions. 
Table 1: The results for Precision 
Injection Area 
Injection-1 1871423 
Injection-2 1876279 
Injection-3 1874529 
Injection-4 1879273 
Injection-5 1873436 
Average 1874987.9 
Standard Deviation 2973.1 
%RSD 0.2 
Acceptance Criteria: The % RSD for the area of five standard 
injections results should not be more than 2%. 
 Precision may be considered at three levels: repeatability, 
intermediate precision and reproducibility. The precision 
of an analytical procedure is usually expressed as the 
variance, standard deviation or coefficient of variation of a 
series of measurements. The standard solutions were 
injected for five times and the area was measured for all five 
injections in HPLC. The %RSD for the area of five replicate 
injections was found to be within the specified limits. The 
data were represented in the Table no.1. 
2. Intermediate Precision: To evaluate the intermediate 
precision (also known as Ruggedness) of the method, 
Precision was performed on different day by using 
different make column of same dimensions. The 
standard solutions were injected for five times and the 
area was measured for all five injections in HPLC. The 
%RSD for the area of five replicate injections was found 
to be within the specified limits. The Data were 
represented in Table no.2. 
Table 2: The results for Intermediate Precision 
(Ruggedness) 
Injection Area 
Injection-1 1869365 
Injection-2 1868938 
Injection-3 1861814 
Injection-4 1867522 
Injection-5 1866552 
Average 1866837.9 
Standard Deviation 3023.9 
%RSD 0.2 
Acceptance Criteria: The % RSD for the area of five standard 
injections results should not be more than 2%. 
3. Accuracy: The accuracy of an analytical procedure 
expresses the closeness of agreement between the 
value which is accepted   either as a conventional true 
value or an accepted reference value and value found.  
The standard solution with Accuracy -50%, Accuracy -
100% and Accuracy -150% solutions were injected to the 
chromatographic system. The amount found was 
calculated and amount added for the drug [Quetiapine] 
was calculated and calculated the individual recovery 
and mean recovery values. The data were represented 
in Table no. 3. 
 
Table 3: The results for Accuracy 
%Concentration 
(at specification Level) 
Area Amount Added (mg) Amount Found (mg) % Recovery Mean Recovery 
50% 2006872 5.0 5.0 100.0% 
     100.5% 100% 4014113 10.0       10.0 100.0% 
150% 6104804 15.0 15.2 101.4% 
Acceptance Criteria: The % Recovery for each level should be between 98.0 to 102.0%. 
4. Linearity: The linearity of the analytical procedure is 
its ability (within a given range) to obtain the test 
results which are directly proportional to the 
concentration (amount) of analyte in the sample. 
Different levels were prepared and injected each level 
into the chromatographic system and the peak area 
was measured. Plotted a graph of peak area versus 
concentration (on X-axis concentration and on Y-axis 
Peak area) and calculated the correlation coefficient. 
The data were represented in Table no.4.  
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Table 4: The results for Linearity 
Sl. No. Linearity Level Concentration Area 
1 I 20µg/ml 1121401 
2 II 30µg/ml 1529276 
3 III 40µg/ml 1879755 
4 IV 50µg/ml 2344717 
5 V 60µg/ml 2766815 
Correlation Coefficient 0.999 
Acceptance Criteria: The Correlation coefficient should be not less than 0.999. 
5. Limit of Detection: The detection limit of an 
individual analytical procedure is the lowest amount 
of analyte in a sample which can be detected but not 
necessarily quantities as an exact value. Several 
approaches for determining the detection limit are 
possible, depending on whether the procedure is a non 
instrumental or instrumental. 
             Calculation of S/N Ratio: 
             Average Baseline Noise obtained from Blank   :    51µV 
             Signal Obtained from LOD solution (0.25% of 
target assay concentration) :    152 µV 
             S/N =        152/51=   2.98 
                   Acceptance Criteria:  The S/N Ratio value 
should be 3 for LOD solution. 
6. Limit of Quantification: The Quantification limit of 
an individual analytical procedure is the lowest 
amount of analyte in a sample which can be 
quantitatively determined with suitable precision and 
accuracy. The Quantification limit is a parameter of 
quantitative assays for low levels of compounds in 
sample matrices, and is used particularly for the 
determination of impurities and/ or degradation 
products. Several approaches for determining the 
Quantification limit are possible, depending on 
whether the procedure is a non- instrumental or 
instrumental. 
Calculation of S/N Ratio: 
             Average Baseline Noise obtained from Blank               :    51µV 
             Signal Obtained from LOD solution (0.75% of 
target assay concentration) :    509 µV 
             S/N =        509/51 =   9.98 
                   Acceptance Criteria: The S/N Ratio value 
should be 10 for LOQ solution. 
7. Robustness: The robustness of an analytical 
procedure is a measure of its capacity to remain 
unaffected by small, but deliberate variations in 
method parameter and provides an indication of its 
reliability during normal usage. As part of the 
Robustness, deliberate change in the Flow rate, 
Mobile Phase composition, Temperature Variation 
was made to evaluate the impact on the method. As 
part of the Robustness, deliberate change in the Flow 
rate, Mobile Phase composition, Temperature 
Variation was made to evaluate the impact on the 
method. 
a) The flow rate was varied at 0.7 to0.9 ml/min. The 
Standard solution 40 µg/ml was prepared and analysed 
using the varied flow rates along with method developed 
flow rate. On evaluation of the above results, it was 
concluded that the variation in flow rate does not affected 
the method significantly. Hence it indicated that the 
method was robust even by change in the flow rate ±10%. 
b) The Organic composition in the Mobile phase was 
varied from70% to 50%.  The Standard solution 40 
µg/ml was prepared and analysed using the varied Mobile 
phase composition along with the actual mobile phase 
composition. On evaluation of the above results, it was 
concluded that the variation in 10% Organic composition 
in the mobile phase does not affected the method 
significantly. Hence it was indicated that the method was 
robust even by change in the Mobile phase ±10%. The 
data were represented in Table no. 5 & 6.
 
Table 5: The results for the Robustness with change in the Flow Rate. 
   
Sl. No. 
 
Flow Rate (ml/min) 
System Suitability Results 
USP Plate Count USP Tailing 
1 0.7 4486 1.5 
2 0.8 4324.4 1.5 
3 0.9 4306 1.4 
 
Table 6: The results for Robustness with change in the Organic Composition in the Mobile Phase 
 Sl. 
No. 
Change in Organic Composition in 
the Mobile Phase  
System Suitability Results 
USP Plate Count USP Tailing 
1 10% less 4758 1.5 
2 *Actual   4324.4        1.5 
3 10% more        3807        1.5 
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8. Degradation studies23: The International 
Conference on Harmonization (ICH) guideline entitled 
stability testing of new drug substances and products 
requires that stress testing be carried out to elucidate the 
inherent stability characteristics of the active substance. 
The aim of this work was to perform the stress degradation 
studies on the Quetiapine Fumarate using the proposed 
method. 
a. Hydrolytic degradation under acidic 
condition: 0.4 ml of stock solution (1000 μg/ml) of the 
drug [Quetiapine Fumarate] was prepared and taken in a 
10 volumetric flask in which 3 ml of 0.1N HCl was added. 
Then the volumetric flask was kept at normal condition for 
90 minutes and then it was neutralized with 0.1 N NaOH 
and the volume was made up to [10ml] with the diluent. 
The resultant solution was filtered with 0.45 microns 
syringe filter and placed in the vial.  
b.  Hydrolytic degradation under alkaline 
condition: 0.4 ml of stock solution (1000 μg/ml) of the 
drug [Quetiapine Fumarate] was prepared and taken in a 
10 ml volumetric flask in which 3 ml of 0.1N NaOH was 
added. Then the volumetric flask was kept at normal 
condition for 90 minutes and then it was neutralized with 
0.1 N HCL and the volume was made up to mark [10ml] 
with the diluent. The resultant solution was filtered with 
0.45 microns syringe filter and placed in the vial.  
c. Thermal induced degradation: 0.4 ml of stock 
solution (1000 μg/ml) of the drug [Quetiapine Fumarate] 
was prepared and taken in a 10 ml volumetric flask in 
which 3 ml of diluent was added. Then the volumetric 
flask was kept at reflex condition for 60 minutes and the 
volume was made up to [10ml] with the diluent. The 
resultant solution was filtered with 0.45 microns syringe 
filter and placed in the vial.  
d. Oxidative degradation: 0.4 ml of the stock 
solution of the drug  [Quetiapine Fumarate] (1000 μg/ml) 
was prepared and taken in 10 ml volumetric flask in which 
1 ml of 3 % w/v of hydrogen peroxide was added and the 
volume was made up to the mark [10ml] with the diluent. 
The volumetric flask was then kept at room temperature 
for 15 min. The resultant solution was filtered with 0.45 
microns syringe filter and placed in the vial.  
e.  Photolytic degradation: The sample of the drug 
[Quetiapine Fumarate] was exposed to near ultra violet 
lamp in Photostablity Chamber providing illumination for 
1hr-5hr. 10 mg of the sample was dissolved in distilled 
water [HPLC grade] and the volume was made up to mark 
[10 ml]. From the above solution dilutions were carried out 
to achieve the appropriate concentration to make 30μg/ml 
and the solution was taken in the vial. 
Table 7: Represented the following results were observed from the degradation studies 
Sl. 
No. 
Degradation Studies Retention 
Time 
Area Height USP Plate 
Count 
USP Tailing 
Factor 
Purity 
Angle 
Purity 
Threshold 
1 Hydrolytic degradation 
under acidic condition 
3.262 2006753 264504 4492.6 1.52 0.53 0.63 
2 Hydrolytic degradation 
under alkaline 
condition 
3.263 1963597 258816 4496.5 1.51 0.32 0.45 
3 Thermal induced 
degradation 
3.260 1920441 253128 4526.9 1.51 0.41 0.53 
4 Oxidative degradation 3.262 1834129 241751 4863.9 1.51 0.26 0.32 
5 Photolytic degradation 3.264 1898863 250283 4321.5 1.51 0.19 0.21 
 
RESULT & DISCUSSION 
The present study was carried out to develop a sensitive, 
precised and accurate stability indicating RP-HPLC 
method for the estimation of Quetiapine Fumarate in bulk 
as well in pharmaceutical dosage form. In order to develop 
the method under isocratic conditions, mixtures of Sodium 
Dihydrogen Phosphate Buffer [with different pH] and 
Methanol [HPLC grade] in different combinations were 
tested as mobile phase on a Symmetry C18 (4.6 x 150mm, 
5 m, Make: Thermo) column. A binary mixture of 
Sodium Dihydrogen Phosphate Buffer [ pH 4.0 adjusted 
with Orthophosphoric acid] and Methanol [HPLC Grade] 
in 35:65 v/v proportion was proved to be the most suitable 
of all combinations since the chromatographic peaks were 
better defined and resolved and almost free from tailing. 
The retention times obtained for the drug [Quetiapine 
Fumarate] was around 2.854 min. A model chromatogram 
was shown in Fig. no.2. 
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Figure 2: A model Chromatograph for the Drug Quetiapine Fumarate 
The Precision data was represented in Table no. 1. When 
Quetiapine was analyzed by the proposed method in the 
intra and inter-day (Ruggedness) variation results, a low 
coefficient of variation was observed and it was 
represented in Table no. 2. This shows that the present 
HPLC method was highly precised and it was represented 
in Fig no. 3. 
 
 
Figure 3: A Model Chromatograph represents the Ruggedness 
The Accuracy recoveries were found to be 100.0-100.4% 
and reproducibility was found to be satisfactory. The 
Accuracy data were summarized in Table no. 3. In order to 
test the linearity of the method, five dilutions of the 
working standard solutions of the drug in the range of 20 
to 60µg per mL were prepared. The data was represented 
in Table no. 4. Each of the dilutions was injected into the 
column and the Linearity Curve was represented in Fig no. 
4.
  
 
Figure 4: Calibration Curve or Linearity Curve for the Drug QuetiapineFumarate 
The method was duly validated by evaluation of the 
required parameters. Robustness of the method was found 
out by testing the effect of small deliberate changes in the 
chromatographic conditions in the chromatographic 
conditions and the corresponding peak areas. The factors 
selected for this purpose was flow rate and percentage 
composition variation in organic phase [Methanol]. The 
method was found to be robust enough that the peak area 
was not apparently affected by small variation in the 
chromatographic conditions. The Fig.no.5, 6, 7 & 8 were 
represented the Robust nature of the chromatograph.  
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Figure 5: The Robustness chromatograph with decrease in the flow rate 
 
Figure 6: The Robustness Chromatograph with increase in the flow rate 
 
 
Figure 7: The Robustness chromatograph with less Mobile Phase composition 
 
Figure 8: The Robustness chromatograph with more Mobile Phase Composition 
The system suitability parameters were within the limits as 
shown in Table 5 and 6 for the drug. Limit of detection and 
limit of quantification of the method were calculated 
basing on standard deviation of the response and the slope 
(s) of the calibration curve at approximate levels of the 
limit of detection and limit of quantification. The LOD for 
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the drug was found to be 0.01µg/ml and LOQ for the Drug 
was found to be 0.03μg/mL.  
In order to evaluate the stability  of Quetiapine Fumarate  
and  ability  of  the  method  to separate Quetiapine 
Fumarate  from  its  degradation  products,  Quetiapine 
Fumarate was subjected to various stress conditions such 
as Hydrolytic degradation under acidic condition (using 
0.1N HCl & 0.1 N NaOH), Hydrolytic degradation under 
alkaline condition (using0.1N NaOH & 0.1N HCL), 
Thermal induced degradation (Reflex Condition for 60 
mins), Oxidative degradation (by using 3 % w/v of 
hydrogen peroxide), Photolytic degradation (exposed to 
near ultra violet lamp in photostablity chamber providing 
illumination for 1hr, 5hr). The following chromatograph 
represents the degradation studies for the drug [Quetiapine 
Fumarate] which were represented in fig. no.9, 10, 11, 12 
& 13. 
 
 
Figure 9: The chromatograph represents the Hydrolytic degradation under acidic condition 
 
Figure 10: The chromatograph represents the Hydrolytic degradation under alkaline condition 
 
Figure 11: The chromatograph represents the Thermal induced degradation 
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Figure 12: The chromatograph represents theOxidative degradation 
 
Figure 13: The chromatograph represents thePhotolytic degradation 
The drug content formulations were quantified by using 
the proposed analytical method. The low coefficient of 
variation in the recovery data indicates the reproducibility 
of the method in dosage forms. It can be concluded that the 
proposed stability indicating HPLC method was 
sufficiently sensitive and reproducible for the analysis of 
Quetiapine in the Tablet formulation dosage forms within 
a short analysis time. 
 
CONCLUSION 
 It can be concluded that the proposed stability indicating 
RP-HPLC method developed for the quantitative 
determination of Quetiapine Fumarate in bulk and in its 
formulations was simple, selective, sensitive, accurate, 
precise and rapid. The method was proved to be superior to 
most of the reported methods. The mobile phases was 
simple to prepare and economical.  The sample recoveries 
in the formulation were in good agreement with their 
respective label claims and they suggested non-
interference of formulation excipients in the estimation. 
Hence this method can easily be adopted as an alternative 
method to reported ones for the routine determination of 
Quetiapine Fumarate depending upon the availability of 
chemicals and nature of other ingredients present in the 
sample. The method also finds use in clinical, biological 
and pharmacokinetic studies of Quetiapine Fumarate. The 
method was validated as per ICH guidelines, and 
validation acceptance criteria were met in all cases. 
Application of this method for estimation of Quetiapine 
Fumarate from tablet dosage form and stressed samples 
showed that neither the degradation products nor the 
excipients interfered in the estimation of drug. Hence, this  
method  was  specific,  stability-indicating  and  can  be  
successfully  used  for  the  estimation  of  Quetiapine 
Fumarate  in  bulk  and pharmaceutical dosage forms.
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